Goh Nicole S L, Veeraraghavan Srihari, Desai Sujal R, Cramer Derek, Hansell David M, Denton Christopher P, Black Carol M, du Bois Roland M, Wells Athol U
Royal Brompton Hospital and National Heart and Lung Institute, London, UK.
Arthritis Rheum. 2007 Jun;56(6):2005-12. doi: 10.1002/art.22696.
To evaluate the prognostic value of bronchoalveolar lavage (BAL) cellular profiles in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD).
BAL cellularity was examined in relation to mortality (n = 141), serial pulmonary function findings (n = 134), and "progression-free survival" (n = 134), by proportional hazards analysis. Baseline severity was quantified according to the extent of disease on high-resolution computed tomography, the diffusing capacity for carbon monoxide, and the presence or absence of pulmonary hypertension. Mortality was subclassified into overall mortality (during 10 years of followup), early mortality (occurring within 2 years of presentation), and late mortality (occurring 2-10 years after presentation).
Overall mortality was associated with neutrophilia on BAL (hazard ratio 2.23 [95% confidence interval 1.20-4.14], P = 0.01), but this effect was lost when disease severity was taken into account. Early mortality was associated with neutrophilia on BAL (hazard ratio 8.40 [95% confidence interval 1.91-36.95], P = 0.005), independent of disease severity. Late mortality was not associated with neutrophilia on BAL. The presence of neutrophilia on BAL was not associated with time to decline in pulmonary function or progression-free survival. Neither eosinophilia nor lymphocytosis on BAL was associated with mortality, rapidity of functional deterioration, or progression-free survival. These findings were unaltered when treatment status was taken into account.
BAL findings provide only limited prognostic information in SSc-ILD. Neutrophilia on BAL is linked to early mortality, but BAL findings are not linked to long-term survival or the rapidity of progression of lung disease. The usefulness of BAL to define alveolitis in SSc is questionable.
评估支气管肺泡灌洗(BAL)细胞谱对系统性硬化症相关间质性肺疾病(SSc-ILD)患者的预后价值。
通过比例风险分析,研究BAL细胞计数与死亡率(n = 141)、系列肺功能检查结果(n = 134)以及“无进展生存期”(n = 134)之间的关系。根据高分辨率计算机断层扫描上的疾病范围、一氧化碳弥散能力以及是否存在肺动脉高压对基线严重程度进行量化。将死亡率分为总死亡率(随访10年期间)、早期死亡率(就诊后2年内发生)和晚期死亡率(就诊后2 - 10年发生)。
总死亡率与BAL中的中性粒细胞增多相关(风险比2.23 [95%置信区间1.20 - 4.14],P = 0.01),但在考虑疾病严重程度后这种效应消失。早期死亡率与BAL中的中性粒细胞增多相关(风险比8.40 [95%置信区间1.91 - 36.95],P = 0.005),与疾病严重程度无关。晚期死亡率与BAL中的中性粒细胞增多无关。BAL中存在中性粒细胞增多与肺功能下降时间或无进展生存期无关。BAL中的嗜酸性粒细胞增多和淋巴细胞增多均与死亡率、功能恶化速度或无进展生存期无关。在考虑治疗状态时,这些结果未改变。
BAL检查结果在SSc-ILD中仅提供有限的预后信息。BAL中的中性粒细胞增多与早期死亡率相关,但BAL检查结果与长期生存或肺部疾病进展速度无关。BAL用于定义SSc中的肺泡炎的实用性值得怀疑。